

# Ifng-Venus-Luc

<b>Nomenclature</b>	C57BL/6Smoc- <i>Ifng</i> <sup>em1(IRES-Venus-Luci)Smoc</sup>
<b>Cat. NO.</b>	NM-KI-18041
<b>Strain State</b>	Embryo cryopreservation

## Gene Summary

<b>Gene Symbol</b> Ifng	<b>Synonyms</b>	Ifg IFN-gamma
	<b>NCBI ID</b>	<a href="#">15978</a>
	<b>MGI ID</b>	<a href="#">107656</a>
	<b>Ensembl ID</b>	<a href="#">ENSMUSG00000055170</a>
	<b>Human Ortholog</b>	IFNG

## Model Description

An IRES-Venus-Luci co-expression cassette was inserted in 3'UTR region of Ifng gene.

\*Literature published using this strain should indicate: Ifng-Venus-Luc mice (Cat. NO. NM-KI-18041) were purchased from Shanghai Model Organisms Center, Inc..

## Validation Data

### MC38-OVA tumor growth




Fig1. MC38-OVA tumor volumes in Ifng-Venus-Luci reporter mice treated or not with anti-PD-1 mAb. Arrows indicate treatment days.




Fig2. In vivo imaging validation of MC38-OVA tumors in Ifng-Venus-Luci reporter mice treated or not with anti-PD-1 mAb.

In PBS treated control tumor, the IFN $\gamma$  signal increased as the tumor growing. In anti-PD1 treated tumor, increased average BLI (Bioluminescent imaging) of IFN $\gamma$  was shown 48h post the first dose compared to control group; as the tumor regression upon PD1 treatment, the IFN $\gamma$  signal in tumor decreased as well.

The data is provided by Crownbio.

